Show simple item record

dc.contributor.authorVan Ganse, Eric
dc.contributor.authorTexier, Nathalie
dc.contributor.authorDima, Alexandra L.
dc.contributor.authorLaforest, Laurent
dc.contributor.authorFerrer, Montserrat
dc.contributor.authorHernandez, Gimena
dc.contributor.authorSchuck, Stéphane
dc.contributor.authorHerbage, Sandrine
dc.contributor.authorVial, Delphine
dc.contributor.authorDe Bruin, Marijn
dc.date.accessioned2015-08-13T15:20:02Z
dc.date.available2015-08-13T15:20:02Z
dc.date.issued2015-06-18
dc.identifier.citationVan Ganse , E , Texier , N , Dima , A L , Laforest , L , Ferrer , M , Hernandez , G , Schuck , S , Herbage , S , Vial , D & De Bruin , M 2015 , ' Assessment of the safety of long-acting β <inf >2 </inf > -agonists in routine asthma care : The ASTRO-LAB protocol ' , npj Primary Care Respiratory Medicine , vol. 25 , 15040 . https://doi.org/10.1038/npjpcrm.2015.40en
dc.identifier.otherPURE: 54985532
dc.identifier.otherPURE UUID: 1b578bb7-ba27-4121-b981-ed766e6a2a39
dc.identifier.otherScopus: 84935005937
dc.identifier.urihttp://hdl.handle.net/2164/4818
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=84935005937&partnerID=8YFLogxKen
dc.descriptionASTRO-LAB is funded by the European Commission through the Seventh Framework Program (FP7-Grant Agreement n° 282 593) and gathers seven partners in a Consortium: Université Claude Bernard Lyon 1, University of Nottingham, Kappa Santé SAS, Cegedim Strategic Data Medical Research Limited, University of Amsterdam, Consortio Mar Parc de Salut de Barcelona and Lyon Ingénierie Projets.en
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofnpj Primary Care Respiratory Medicineen
dc.rightsThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectRA Public aspects of medicineen
dc.subjectPublic Health, Environmental and Occupational Healthen
dc.subjectPulmonary and Respiratory Medicineen
dc.subject.lccRAen
dc.titleAssessment of the safety of long-acting β<inf>2</inf> -agonists in routine asthma care : The ASTRO-LAB protocolen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.University of Aberdeenen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Health Psychology Groupen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1038/npjpcrm.2015.40
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84935005937&partnerID=8YFLogxKen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record